Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK,
Transl Stroke Res. 2011 Sep;2(3):266-71. doi: 10.1007/s12975-011-0095-z. Epub 2011 Jul 26.
The method of delivery of stem cells is a major factor to consider in the design of clinical trials of cell therapy. Different methods of delivery will be associated with different risks to the patient, and may also be associated with different potential for benefit. Current approaches are partly informed by the routes selected for study in animal models of focal ischaemia and CNS transplantation, but there has been little work comparing the efficacy of different routes of administration. Direct intraparenchymal delivery of cells has been employed in several preliminary clinical trials, and data on the safety of this approach are reviewed.
干细胞的递送方法是细胞治疗临床试验设计中需要考虑的主要因素。不同的递送方法会给患者带来不同的风险,也可能与不同的潜在益处相关。目前的方法部分是根据局灶性缺血和中枢神经系统移植的动物模型中选择的研究途径来确定的,但比较不同给药途径的疗效的工作却很少。细胞的直接脑室内递送已在几项初步临床试验中得到应用,本文回顾了这种方法的安全性数据。